Chronix Biomedical looking to distinguish prostate cancer from BPH and prostatitis
Chronix Biomedical looking to distinguish prostate cancer from BPH and prostatitis
Pharmaceuticals, Biotechnology and Life Sciences
Chronix Biomedical looking to distinguish prostate cancer from BPH and prostatitis
Pfizer announced today the discontinuation of the global clinical development program for bococizumab…
Allergan has completed the acquisition of Tobira Therapeutics
Novartis gets FDA Priority Review for first-line treatment of HR+/HER2-advanced breast cancer
India’s Strides Shasun Limited has received approval from the USFDA for Abacavir Tablets
Avacta Group will present detailed data from the first pre-clinical in-vivo studies of its therapeutic Affimer platform
Advanced Oncotherapy has announced that Lord David Evans has stepped down
French Genfit has raised €78.5 million and invests in its R&D
Mylan NV’s price hikes on EpiPens have added millions to U.S. Department of Defense spending…
BD has gotten FDA market authorization for a first-of-its-kind molecular test…